This is what analysts have to say about SteadyMed Ltd. (NASDAQ:STDY) after last week.

June 17, 2018 - By reb123z

SteadyMed Ltd. (NASDAQ:STDY) Logo

SteadyMed Ltd. (NASDAQ:STDY) Ratings Coverage

Among 2 analysts covering Steadymed (NASDAQ:STDY), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Steadymed had 3 analyst reports since January 10, 2018 according to SRatingsIntel. On Tuesday, May 1 the stock rating was downgraded by JMP Securities to “Market Perform”. On Monday, April 9 the stock rating was maintained by H.C. Wainwright with “Buy”. Below is a list of SteadyMed Ltd. (NASDAQ:STDY) latest ratings and price target changes.

01/05/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Perform Downgrade
09/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $15.0000 Maintain
10/01/2018 Broker: JMP Securities Rating: Buy

It closed at $4.45 lastly. It is up 34.29% since June 17, 2017 and is downtrending. It has underperformed by 46.86% the S&P500.

SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical firm that focuses on the development and commercialization of drug product candidates for the treatment of orphan and other diseases with unmet parenteral delivery needs. The company has market cap of $118.25 million. The companyÂ’s product candidates are enabled by its proprietary PatchPump, a discreet, pre-filled, water-resistant, and disposable parenteral drug administration technology. It currently has negative earnings. The Company’s lead drug product candidate is Trevyent, a development stage drug that combines PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue for treating pulmonary arterial hypertension.

SteadyMed Ltd. (NASDAQ:STDY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.